# OnCo record lenvatinib-plus-pembrolizumab (pairing). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/pairings/lenvatinib-plus-pembrolizumab/>
  a schema:MedicalTherapy ;
  onco:kind "pairing" ;
  schema:identifier "lenvatinib-plus-pembrolizumab" ;
  schema:name "Lenvatinib + pembrolizumab (pMMR endometrial cancer after platinum)"@en ;
  schema:description "An anti-angiogenic pill makes immunotherapy work in endometrial cancers that would otherwise ignore it, at the cost of significant side effects."@en ;
  schema:url <https://onco.cc/pairings/lenvatinib-plus-pembrolizumab/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03517449> ;
  onco:related <https://onco.cc/pairings/io-plus-vegf/> ;
  onco:cancers <https://onco.cc/cancers/endometrial/> ;
  onco:targets <https://onco.cc/targets/vegf/>, <https://onco.cc/targets/pd1/> ;
  onco:trials <https://onco.cc/trials/keynote-775/> ;
  onco:pairs <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/pembrolizumab/> .